Abstract
Cardiac structure and function were evaluated by two-dimensional, M-mode and Doppler echocardiograms in eight adults with childhood-onset growth hormone deficiency (GHD) before and after 6 months .of growth hormone (GH) therapy, 0.5 ID/kg/week. An exercise test was also performed using a modified Bruce protocol, with a bicycle ergometer. Before therapy, values (mean ±SEM) for intraventricular septa) thickness (7.1 ±0.3 mm), left ventricular (LV) posterior wall thickness (LVPT; 5.2 ±0.1 mm), LV mass (LVM; 46.6 ±5.6 g), LVM index (LVM/body surface area; LVMI; 33.9 ±2.6 g/m2), LV end-diastolic diameter (41.5 ±0.6 mm) and LV ejection time (LVET; 251.2 ±10.6 milliseconds) in patients with GHD were lower (P<0.001) than those in controls, while LV pre-ejection period (PEP)/LVET (0.36 ±0.02) values were higher (P <0.01). LV end-systolic diameter, PEP, ejection fraction and parameters of LV diastolic function (peak protodiastolic velocity (E), peak telediastolic velocity (A) and E/A) in patients were similar to those in the controls. GH therapy increased (P <0.0001) LVPT (6.8 ±0.2 mm), LVM (57.4 ±5.3 g) and LVMI (41.7 ±2.2 g/m2) and reduced PEP (76.7 ±1.7 milliseconds; P<0.0001), LVET (236 ±8.0 milliseconds; P <0.05) and PEP/LVET (0.32 ±0.01; P<0.01) values; no significant changes were observed for the other parameters. The exercise test showed a significant improvement in cardiac performance, as demonstrated by a reduction in the product of blood pressure x heart rate at the same workload (basal, 33067 ±842; after GH, 25638 ±444; P<0.0001). These findings support a role for GH in the maintenance of normal cardiac performance in adults and suggest that GH treatment might ameliorate the cardiac structure and function of patients with GHD. To date, the long-term effects of this therapy on the future prognosis of adults with GHD remain to be clarified.
| Original language | English |
|---|---|
| Pages (from-to) | 132 |
| Number of pages | 1 |
| Journal | Endocrinology and Metabolism, Supplement |
| Volume | 3 |
| Issue number | SUPPL. A |
| Publication status | Published - 1996 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
Cite this
Cardiovascular effects of growth hormone therapy in adults with childhood-onset growth hormone deficiency. / Sartorio, A.; Ferrero, S.; Conti, A.; Bragato, R.; Leonetti, G.; Faglia, G.
In: Endocrinology and Metabolism, Supplement, Vol. 3, No. SUPPL. A, 1996, p. 132.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cardiovascular effects of growth hormone therapy in adults with childhood-onset growth hormone deficiency
AU - Sartorio, A.
AU - Ferrero, S.
AU - Conti, A.
AU - Bragato, R.
AU - Leonetti, G.
AU - Faglia, G.
PY - 1996
Y1 - 1996
N2 - Cardiac structure and function were evaluated by two-dimensional, M-mode and Doppler echocardiograms in eight adults with childhood-onset growth hormone deficiency (GHD) before and after 6 months .of growth hormone (GH) therapy, 0.5 ID/kg/week. An exercise test was also performed using a modified Bruce protocol, with a bicycle ergometer. Before therapy, values (mean ±SEM) for intraventricular septa) thickness (7.1 ±0.3 mm), left ventricular (LV) posterior wall thickness (LVPT; 5.2 ±0.1 mm), LV mass (LVM; 46.6 ±5.6 g), LVM index (LVM/body surface area; LVMI; 33.9 ±2.6 g/m2), LV end-diastolic diameter (41.5 ±0.6 mm) and LV ejection time (LVET; 251.2 ±10.6 milliseconds) in patients with GHD were lower (P<0.001) than those in controls, while LV pre-ejection period (PEP)/LVET (0.36 ±0.02) values were higher (P <0.01). LV end-systolic diameter, PEP, ejection fraction and parameters of LV diastolic function (peak protodiastolic velocity (E), peak telediastolic velocity (A) and E/A) in patients were similar to those in the controls. GH therapy increased (P <0.0001) LVPT (6.8 ±0.2 mm), LVM (57.4 ±5.3 g) and LVMI (41.7 ±2.2 g/m2) and reduced PEP (76.7 ±1.7 milliseconds; P<0.0001), LVET (236 ±8.0 milliseconds; P <0.05) and PEP/LVET (0.32 ±0.01; P<0.01) values; no significant changes were observed for the other parameters. The exercise test showed a significant improvement in cardiac performance, as demonstrated by a reduction in the product of blood pressure x heart rate at the same workload (basal, 33067 ±842; after GH, 25638 ±444; P<0.0001). These findings support a role for GH in the maintenance of normal cardiac performance in adults and suggest that GH treatment might ameliorate the cardiac structure and function of patients with GHD. To date, the long-term effects of this therapy on the future prognosis of adults with GHD remain to be clarified.
AB - Cardiac structure and function were evaluated by two-dimensional, M-mode and Doppler echocardiograms in eight adults with childhood-onset growth hormone deficiency (GHD) before and after 6 months .of growth hormone (GH) therapy, 0.5 ID/kg/week. An exercise test was also performed using a modified Bruce protocol, with a bicycle ergometer. Before therapy, values (mean ±SEM) for intraventricular septa) thickness (7.1 ±0.3 mm), left ventricular (LV) posterior wall thickness (LVPT; 5.2 ±0.1 mm), LV mass (LVM; 46.6 ±5.6 g), LVM index (LVM/body surface area; LVMI; 33.9 ±2.6 g/m2), LV end-diastolic diameter (41.5 ±0.6 mm) and LV ejection time (LVET; 251.2 ±10.6 milliseconds) in patients with GHD were lower (P<0.001) than those in controls, while LV pre-ejection period (PEP)/LVET (0.36 ±0.02) values were higher (P <0.01). LV end-systolic diameter, PEP, ejection fraction and parameters of LV diastolic function (peak protodiastolic velocity (E), peak telediastolic velocity (A) and E/A) in patients were similar to those in the controls. GH therapy increased (P <0.0001) LVPT (6.8 ±0.2 mm), LVM (57.4 ±5.3 g) and LVMI (41.7 ±2.2 g/m2) and reduced PEP (76.7 ±1.7 milliseconds; P<0.0001), LVET (236 ±8.0 milliseconds; P <0.05) and PEP/LVET (0.32 ±0.01; P<0.01) values; no significant changes were observed for the other parameters. The exercise test showed a significant improvement in cardiac performance, as demonstrated by a reduction in the product of blood pressure x heart rate at the same workload (basal, 33067 ±842; after GH, 25638 ±444; P<0.0001). These findings support a role for GH in the maintenance of normal cardiac performance in adults and suggest that GH treatment might ameliorate the cardiac structure and function of patients with GHD. To date, the long-term effects of this therapy on the future prognosis of adults with GHD remain to be clarified.
UR - http://www.scopus.com/inward/record.url?scp=33748014333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748014333&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:33748014333
VL - 3
SP - 132
JO - Endocrinology and Metabolism, Supplement
JF - Endocrinology and Metabolism, Supplement
SN - 1074-939X
IS - SUPPL. A
ER -